Kou Qin, PhD

艾科联生物专注于挖掘T细胞免疫治疗的无限可能，依托自主研发的专有T细胞衔接器（TCE）多抗平台，致力于开发差异化程度更高、临床潜力更强的下一代TCE创新药物。艾科联生物聚焦实体肿瘤和自身免疫疾病治疗等复杂治疗领域，旨在为全球患者提供更优化、更可及的治疗方案。 Excalipoint is committed to unlocking the boundless potential of T-cell based therapeutics. We leverage our unique and proprietary T-cell engager (TCE) multi-specific antibody platform to discover and develop highly differentiated next-generation TCE therapies, for improved treatment options in solid tumor and autoimmune diseases.

Vivacta is a biotech company spun out from global leading investors, dedicated to advancing in vivo CAR-T therapies.

eGenesis is revolutionizing the field of transplantation with an unparalleled, multiplexed gene editing platform for the development of human-compatible organs, tissues and cells. Harnessing the latest gene-editing techniques, eGenesis’ mission is to solve the global organ shortage crisis by developing a scalable alternative to allotransplantation. eGenesis is reinvigorating the field of xenotransplantation by addressing the key virology and immunology hurdles that have prevented its advancement to date, and is developing commercially-viable products to save and improve the lives of patients who are waiting for an organ transplant.

Iambic is a clinical-stage AI biotech developing novel medicines using its AI-driven platform. Based in San Diego and founded in 2020, Iambic has assembled a world-class team that unites pioneering AI experts and experienced drug hunters. The Iambic platform has demonstrated delivery of new drug candidates to human clinical trials with industry-leading speed and across multiple target classes and mechanisms of action. Iambic is advancing a pipeline of potential best-in-class and first-in-class clinical assets to address urgent unmet patient need. Learn more at iambic.ai

With a singular goal to improve patient lives, Hyku is pioneering precise covalent targeting of disease-causing proteins and transforming conventional treatment paradigms

The vast majority of human disease is governed by the epigenome, the subtle machinery that controls the volume of gene expression in cells. Tune Therapeutics is pioneering the creation of epi-therapeutic medicines with its powerful and precise epigenomic control platform, TEMPO. Unlike genome editing, TEMPO dials the volume of gene expression up or down towards healthy levels, without breaking or permanently rewriting DNA – and it can do this in multiple genes at once. This genetic tuning approach allows us to change cell fate and function at will, unlocking the ability to reverse pathways of cancer, genetic disease and aging. Our approach effectively expands the potential reach of genetic medicine – from targeting a limited range of rare conditions, to overcoming thousands of complex and chronic diseases that currently have no curative treatment.

Were harnessing the natural cellular process of autophagy to design powerful new medicines for a broad range of diseases.

Travera uses a breakthrough measurement tool invented at MIT to directly measure which cancer drugs are most likely to be effective for each individual cancer patient prior to them taking the drugs. The company offers CLIA certified Rapid Therapy Guidance Tests for all major cancers and 100+ FDA-approved cancer drugs, with a turnaround time of only two days.

Inappropriate activation of the immune system results in the majority of human diseases. Thus, modulation of immune system is the focus of many drug research and development programs, which are targeting inflammation-related diseases as diverse as cancer, sepsis and Alzheimer’s. Pyrotech Therapeutics is a newcomer in this field but is rapidly become world-recognized for its innovative science and first-in-class programs. Pyrotech is based on ground-breaking discoveries in the laboratory of its scientific co-founder regarding ‘pyroptosis’, which is a type of cell death that controls infections by stimulating strong immune responses. However, this often beneficial highly inflammatory cell death occurs not only in the presence of pathogens but also results from other types of stimuli and injuries. Consequently, an exaggerated or inappropriate immune response can result in both acute and chronic harm to many organs. Identifying molecules that inhibit excessive and harmful immune reactions is one cornerstone of Pyrotech’s programs. Conversely, Pyrotech has also discovered molecules that can exaggerate pyroptosis in cancer cells; these can lead to the eradication of tumors. Pyrotech was founded in early 2021 by Professor Feng Shao of the National Institute of Biological Sciences, Beijing, and Dr. TJ Deng, formerly the CEO of BioDuro China. In just one year, Pyrotech has built a 40,000-square feet of start-of-the-art research center in the Life Science Park of Beijing, and smaller facilities in Shanghai and San Diego. As of today, it employs 100+ experts in drug discovery, medicinal chemistry and clinical development. Several of the company’s small molecule and biologic immune modulators are advancing quickly into clinical studies and the pipeline continues to expand. Pyrotech aspires to become the first China-centric biopharmaceutical company that competes and partners globally with established major pharma companies.

Orange Health is Indias leading on-demand diagnostic lab. Our vision is to make healthcare seamless for consumers in their homes by enabling doctors to treat their patients in real-time. To do this, we provide 60 min at-home testing for over 2,000 tests along with fast results. Consumers love this, and have rated Orange Health 4.9/5 on Google - among the highest-rated diagnostic labs in India! We combine the latest consumer tech experience with the veracity of high-quality healthcare, giving consumers a mind-blowing experience, where they say its easier than ordering a pizza Launched in Bangalore, Gurgaon & Noida. Coming soon to every city! Backed by leading global investors, we have a team of experienced leaders, operators, engineers, medical professionals, and more - all of whom love making healthcare better for people like you and us! We are a team that loves our work and play. We love people with varied interests. We have hockey players, pianists, competitive swimmers, marathoners, science geeks, gamers, mountaineers, sailors, models, bikers, singers, boxers, vada-pav lovers, coffee afficionados, chocoholics and more. Come add to this list!

Kernal creates mRNA therapies to cure severe diseases including cancer. Our mRNA therapies instruct specific cells on how to make their own drugs. With roots at MIT, Harvard and Big Pharma, our team previously built a successful Biotech company and has deep expertise in mRNA space.

Were a team of clinicians, engineers, and operators fundamentally redesigning how healthcare works for the 80 million uninsured and under-insured Americans. We started with a simple vertically integrated primary and urgent care health plan designed to make high-quality concierge care accessible to everyone - from the Grammy winners that have used us to our uninsured members. Our network of providers comes directly to our members, either virtually or through in-home concierge visits.

Who we are Established at the end of 2020, TTM Capital is a professional investment firm focusing on early and growth-stage investments in the life science and healthcare sectors. We focus on selective and exceptional investment opportunities in biopharmaceuticals, medical devices, in vitro diagnostics, and “medical+”, driven by cutting-edge technologies. In such rigorous approach, we concentrate on niche markets with significant advantages, and pay close attention to the "unmet needs" of the global medical market and patients. Our team has been deeply involved in the medical and biotechnology sectors for many years, with extensive backgrounds in medical investments for years at top investment funds and over decades of experience in the entire industrial chain of leading global pharmaceutical companies. We always adhere to our original aspirations, focus on the long term, navigate through cycles, equip with global perspective, and build an efficient ecosystem that integrates dots seamlessly across capital, enterprises, spaces, academia, talents, and projects. We persistently empower invested companies and create synergy, jointly promote medical innovation, and benefit society in return. What we do Comprehensive linkage: Linking the core resources of the medical industry, schools, government, and investment, complementing and empowering each other, achieving mutual success. Multi-disciplinary sourcing: Leverage the funds professional advantages, and create ventures together with technical experts and business talents, enhance the possibility of investing in unicorns. Strategic alliance: United effort with determined co-operation, with common aspirations, to achieve long-term win-win.

艾科联生物专注于挖掘T细胞免疫治疗的无限可能，依托自主研发的专有T细胞衔接器（TCE）多抗平台，致力于开发差异化程度更高、临床潜力更强的下一代TCE创新药物。艾科联生物聚焦实体肿瘤和自身免疫疾病治疗等复杂治疗领域，旨在为全球患者提供更优化、更可及的治疗方案。 Excalipoint is committed to unlocking the boundless potential of T-cell based therapeutics. We leverage our unique and proprietary T-cell engager (TCE) multi-specific antibody platform to discover and develop highly differentiated next-generation TCE therapies, for improved treatment options in solid tumor and autoimmune diseases.

Vivacta is a biotech company spun out from global leading investors, dedicated to advancing in vivo CAR-T therapies.

eGenesis is revolutionizing the field of transplantation with an unparalleled, multiplexed gene editing platform for the development of human-compatible organs, tissues and cells. Harnessing the latest gene-editing techniques, eGenesis’ mission is to solve the global organ shortage crisis by developing a scalable alternative to allotransplantation. eGenesis is reinvigorating the field of xenotransplantation by addressing the key virology and immunology hurdles that have prevented its advancement to date, and is developing commercially-viable products to save and improve the lives of patients who are waiting for an organ transplant.

Iambic is a clinical-stage AI biotech developing novel medicines using its AI-driven platform. Based in San Diego and founded in 2020, Iambic has assembled a world-class team that unites pioneering AI experts and experienced drug hunters. The Iambic platform has demonstrated delivery of new drug candidates to human clinical trials with industry-leading speed and across multiple target classes and mechanisms of action. Iambic is advancing a pipeline of potential best-in-class and first-in-class clinical assets to address urgent unmet patient need. Learn more at iambic.ai